Antitrust & Competition Policy Blog

Editor: D. Daniel Sokol
University of Florida
Levin College of Law

A Member of the Law Professor Blogs Network

Saturday, January 1, 2011

AALS Annual Meeting, Section on Antitrust and Economic Regulation Presents - Drug Wars: The Battle Over Generic Pharmaceuticals

Posted by D. Daniel Sokol

For those who will be attending the AALS meeting, our Section on Antitrust and Economic Regulation will sponsor

Drug Wars: The Battle Over Generic Pharmaceuticals

(Papers will be published in the Hastings Science and Technology Journal)

2011 Annual Meeting
Date: January 5 — 8, 2011
Location: Hilton San Francisco Union Square
 

Moderator: Robin C. Feldman, University of California Hastings College of the Law

Speakers: Michael A. Carrier, Rutgers School of Law - Camden

Daniel A. Crane, The University of Michigan Law School

Richard A. Epstein, New York University School of Law

Scott Hemphill, Columbia University School of Law

Mark A. Lemley, Stanford Law School

Catherine J. Sandoval, Santa Clara University School of Law

When patents on branded drugs expire and generics enter the market, drug prices tend to drop dramatically. As a result, getting generic drugs on the shelves is an important part of controlling health care costs. In recent years, however, drug companies have found increasingly creative methods of filing suits, striking deals, and entering into settlements that have the effect of delaying or lessening generic competition. Are these arrangements problematic under current law? What role can antitrust law play in monitoring them?

http://lawprofessors.typepad.com/antitrustprof_blog/2011/01/aals-annual-meeting-section-on-antitrust-and-economic-regulation-presents-drug-wars-the-battle-over-.html

| Permalink

TrackBack URL for this entry:

http://www.typepad.com/services/trackback/6a00d8341bfae553ef0148c7394cf0970c

Listed below are links to weblogs that reference AALS Annual Meeting, Section on Antitrust and Economic Regulation Presents - Drug Wars: The Battle Over Generic Pharmaceuticals:

Comments

Post a comment